Mechanisms and Biologic Treatment Strategies in Immune-Mediated Ocular  Inflammation

Javeria Sarfraz, Sidra Ahsan Shah, Muhammad Imran Ali, Tariq Pervaiz Khan, Usama Hasnat, Abdul Munim

Mechanisms and Biologic Treatment Strategies in Immune-Mediated Ocular Inflammation

Authors

Javeria Sarfraz, Sidra Ahsan Shah, Muhammad Imran Ali, Tariq Pervaiz Khan, Usama Hasnat, Abdul Munim

Keywords:

immune-mediated ocular inflammation, biologic therapy, uveitis

Abstract

Immune-mediated ocular inflammation (IMOI) encompasses a spectrum of non-infectious uveiticconditions that can lead to significant visual impairment. This study aimed to evaluate the efficacyand safety of biologic therapies—specifically adalimumab, infliximab, and Janus kinase (JAK)

References

Liu W, Bai D, Kou L. Comparison of infliximab with adalimumab for the treatment of noninfectious uveitis: a systematic review and meta-analysis. BMC Ophthalmol. 2021;23:240. DOI: https://doi.org/10.1186/s12886-023-02987-1

Downloads

Published

2025-05-29

How to Cite

Javeria Sarfraz, Sidra Ahsan Shah, Muhammad Imran Ali, Tariq Pervaiz Khan, Usama Hasnat, Abdul Munim. (2025). Mechanisms and Biologic Treatment Strategies in Immune-Mediated Ocular Inflammation . International Journal of Pharmacy Research & Technology (IJPRT), 15(1), 1357–1368. Retrieved from https://www.ijprt.org/index.php/pub/article/view/580